Understand shoulder regeneration as care, not proof of new tissue

Ask what will be used in your shoulder

Biologic therapies means office procedures prepared from a person's blood, marrow, or fat. The broad name doesn't mean one clinic uses all three materials. Ask which material will be used and whether it came from blood, marrow, or fat.

Clinics use PRP to mean platelet-rich plasma, a liquid made after drawing and spinning blood. The spinning leaves extra platelets in the liquid; these tiny blood pieces take part in repair. Concentrated PRP simply means the finished liquid holds more platelets than ordinary blood.

Check whether the result was relief or repair

A shoulder can move more easily even when an MRI still looks the same. That matters if you can sleep, dress, or reach with less soreness. It just isn't proof that a tendon or the smooth joint covering grew back.

The reverse can happen after surgery. A repaired tendon may look better on a scan without feeling much better. Research about scan images doesn't answer your soreness question unless it also measured what people felt and could do.

Ask what happens if nothing changes

Human shoulder research on PRP gives mixed answers. Some reports show a small benefit months later, while others find no change large enough to notice. None proves that an office procedure rebuilds a torn shoulder tendon that has never had surgery.

Ask when you might notice relief and when it may fade. Find out the cost, the limits, and the date for another shoulder check. A plain answer matters more than a promising treatment name.

Sources

1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

   Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

2. A Nature comment by Sipp, Robey and Turner arguing that loose use of 'mesenchymal stem cell' across an enormous range of unrelated cell preparations has produced a scientific and commercial mess, and calling for the terminology and the evidentiary standards to be tightened. Included because the objection to the word comes from inside stem cell science, not from its critics.

   Sipp D, et al. — Clear up this stem-cell mess.. Nature, 2018. DOI: 10.1038/d41586-018-06756-9.

3. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product.

   Tan AR, et al. — Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.16-0271.

4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

5. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

6. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, 2024.

7. FDA's public list of licensed cellular and gene therapy products is the checkable answer to 'is this FDA-approved?'. A product not on that list, and not being administered under an active IND, is not an approved therapy however it is described in a brochure. For orthopedics the list is short and its cartilage entry is MACI, indicated for focal full-thickness knee defects.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Approved Cellular and Gene Therapy Products. FDA, 2026.